Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

ASP7317

Source date not recordedAnalyse record ↗

Stem-cell-derived retinal pigment epithelium replacement therapy in recruiting early clinical development for geographic atrophy in dry AMD.

Modality
subretinal human embryonic stem-cell-derived retinal pigment epithelium cell therapy
Availability (US)
ClinicalTrials.gov Phase 1 study Recruiting; Astellas describes the current dose-escalation program as Phase 1b
Biomarkers
treatment-emergent adverse events; graft failure or rejection; best-corrected visual acuity; retinal imaging
Hallmark targeted
stem-cell-based tissue replacement, loss of regenerative capacity, retinal degeneration
Kind
investigational cell therapy
Clinical trials
NCT03178149 — Phase 1, Recruiting on September 3, 2026 registry update